Hutchison China MediTech Limited (LON:HCM) insider Michael Howell sold 3,000 shares of the business’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of GBX 1,890 ($23.61), for a total transaction of £56,700 ($70,839.58).

Michael Howell also recently made the following trade(s):

  • On Monday, October 24th, Michael Howell sold 339 shares of Hutchison China MediTech Limited stock. The shares were sold at an average price of GBX 1,825 ($22.80), for a total transaction of £6,186.75 ($7,729.57).
  • On Tuesday, October 25th, Michael Howell sold 1,000 shares of Hutchison China MediTech Limited stock. The shares were sold at an average price of GBX 1,840 ($22.99), for a total transaction of £18,400 ($22,988.51).
  • On Wednesday, October 26th, Michael Howell sold 3,000 shares of Hutchison China MediTech Limited stock. The shares were sold at an average price of GBX 1,850 ($23.11), for a total transaction of £55,500 ($69,340.33).
  • On Friday, October 28th, Michael Howell sold 2,500 shares of Hutchison China MediTech Limited stock. The shares were sold at an average price of GBX 1,860 ($23.24), for a total transaction of £46,500 ($58,095.95).
  • On Friday, October 7th, Michael Howell sold 15,000 shares of Hutchison China MediTech Limited stock. The shares were sold at an average price of GBX 1,790 ($22.36), for a total transaction of £268,500 ($335,457.27).

Hutchison China MediTech Limited (LON:HCM) opened at 1925.00 on Wednesday. The stock has a 50 day moving average of GBX 1,852.43 and a 200 day moving average of GBX 1,852.83. The firm’s market capitalization is GBX 1.17 billion. Hutchison China MediTech Limited has a one year low of GBX 1,612.50 and a one year high of GBX 2,896.60.

Several brokerages have recently commented on HCM. Beaufort Securities restated a “buy” rating on shares of Hutchison China MediTech Limited in a report on Tuesday, November 1st. Panmure Gordon restated a “buy” rating and issued a GBX 2,630 ($32.86) price objective on shares of Hutchison China MediTech Limited in a report on Monday, October 31st.

COPYRIGHT VIOLATION WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and republished in violation of U.S. & international copyright laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/23/michael-howell-sells-3000-shares-of-hutchison-china-meditech-limited-hcm-stock.html.

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Stock Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related stocks with our FREE daily email newsletter.